Departing Alnylam, Greene has messages for industry from company building to product pricing

As Barry Greene departs Alnylam, he believes the modality he nurtured from plan to reality has the potential to sit alongside mAbs and small molecules as an agent of choice.

Greene announced in August that he would leave his role as president of Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY) Sept. 30, after 17 years working side by side with CEO John Maraganore. ...